| Literature DB >> 30229030 |
Ogbiye A Samuel1, Tenebe I Theophilus1, Emenike C Praise God1,2, Anake U Winifred3.
Abstract
Heavy metals find their way into surface and groundwater due to degrading environmental conditions, and as such consistent monitoring to avoid the adverse health implications associated with the consumption of polluted water is required. This study examined the concentrations for Lead (Pb), Nickel (Ni), Zinc (Zn), Chromium (Cr), Cadmium (Cd), Copper (Cu) and Arsenic (As) in the Surface water of River Balogun in Ota, Ogun State, Nigeria during the wet season and estimated the human health risk resulting from prolonged consumption by children and adult of dissimilar age groups without treatment. Although there were persistent occurrence of Nickel (Ni), Copper (Cu), Zinc (Zn) and Arsenic (As) in all stations sampled, the health risk assessment conducted revealed that both population groups are more likely to be affected by high concentration levels of Arsenic than any other Heavy metal present.Entities:
Year: 2018 PMID: 30229030 PMCID: PMC6141265 DOI: 10.1016/j.dib.2018.06.051
Source DB: PubMed Journal: Data Brief ISSN: 2352-3409
Fig. 1Map of study area showing sampling locations.
Individual metal concentration of analyzed river water samples (Nd=51 from 17 different locations).
| Cu (mg/L) | Zn (mg/L) | Ni (mg/L) | Cr (mg/L) | Cd (mg/L) | Pb (mg/L) | As (mg/L) | |
|---|---|---|---|---|---|---|---|
| ST1 | 0.08 | 0.20 | 0.03 | ND | ND | 0.00 | 0.04 |
| ST2 | 0.08 | 0.11 | 0.03 | ND | ND | 0.00 | 0.04 |
| ST3 | 0.07 | 0.10 | 0.03 | ND | ND | 0.00 | 0.05 |
| ST4 | 0.06 | 0.23 | 0.01 | ND | ND | 0.01 | 0.05 |
| ST5 | 0.05 | 0.21 | 0.01 | ND | ND | 0.01 | 0.05 |
| ST6 | 0.05 | 0.24 | 0.01 | ND | ND | 0.01 | 0.05 |
| ST7 | 0.06 | 0.14 | 0.01 | ND | ND | 0.00 | 0.04 |
| ST8 | 0.06 | 0.22 | 0.01 | ND | ND | 0.00 | 0.03 |
| ST9 | 0.06 | 0.13 | 0.01 | ND | ND | 0.00 | 0.03 |
| ST10 | 0.06 | 0.33 | 0.02 | ND | ND | 0.00 | 0.03 |
| ST11 | 0.06 | 0.79 | 0.02 | ND | ND | 0.00 | 0.03 |
| ST12 | 0.06 | 0.29 | 0.02 | ND | ND | 0.00 | 0.05 |
| ST13 | 0.07 | 0.44 | 0.02 | ND | ND | 0.00 | 0.03 |
| ST14 | 0.07 | 0.51 | 0.02 | ND | ND | 0.00 | 0.04 |
| ST15 | 0.07 | 0.39 | 0.03 | ND | ND | 0.00 | 0.06 |
| ST16 | 0.07 | 0.53 | 0.03 | ND | ND | 0.00 | 0.06 |
| ST17 | 0.07 | 0.30 | 0.03 | ND | ND | 0.00 | 0.08 |
| ST18 | 0.05 | 0.45 | 0.01 | ND | ND | 0.01 | 0.05 |
| ST19 | 0.05 | 0.53 | 0.01 | ND | ND | 0.01 | 0.05 |
Oral reference dose (RfD).
| Metals | RfD ingestion (mg/kg/day) |
|---|---|
| Arsenic (As) | 3.00E−4 |
| Copper (Cu) | 3.70E−2 |
| Nickel (Ni) | 2.00E−2 |
| Zinc (Zn) | 3.00E−01 |
| Lead (Pb) | 3.50E−03 |
*NA=Not Applicable.
Average daily dose (ADD) via ingestion pathway for Cu concentration.
| (6–12 months) | (6–11 years) | (11–16 years) | (16–18 years) | (18–21 years) | (≥21 years) | (>65 years) | |
|---|---|---|---|---|---|---|---|
| ST1 | 8.791 | 3.604 | 2.686 | 2.107 | 2.769 | 2.985 | 2.730 |
| ST2 | 8.462 | 3.469 | 2.586 | 2.028 | 2.665 | 2.873 | 2.628 |
| ST3 | 8.132 | 3.334 | 2.485 | 1.949 | 2.562 | 2.761 | 2.525 |
| ST4 | 6.264 | 2.568 | 1.914 | 1.501 | 1.973 | 2.127 | 1.945 |
| ST5 | 5.934 | 2.433 | 1.813 | 1.422 | 1.869 | 2.015 | 1.843 |
| ST6 | 5.934 | 2.433 | 1.813 | 1.422 | 1.869 | 2.015 | 1.843 |
| ST7 | 6.154 | 2.523 | 1.880 | 1.475 | 1.938 | 2.089 | 1.911 |
| ST8 | 6.264 | 2.568 | 1.914 | 1.501 | 1.973 | 2.127 | 1.945 |
| ST9 | 6.374 | 2.613 | 1.948 | 1.527 | 2.008 | 2.164 | 1.979 |
| ST10 | 6.484 | 2.658 | 1.981 | 1.554 | 2.042 | 2.201 | 2.013 |
| ST11 | 6.593 | 2.703 | 2.015 | 1.580 | 2.077 | 2.239 | 2.048 |
| ST12 | 6.923 | 2.838 | 2.115 | 1.659 | 2.181 | 2.351 | 2.150 |
| ST13 | 7.143 | 2.928 | 2.183 | 1.712 | 2.250 | 2.425 | 2.218 |
| ST14 | 7.143 | 2.928 | 2.183 | 1.712 | 2.250 | 2.425 | 2.218 |
| ST15 | 7.253 | 2.973 | 2.216 | 1.738 | 2.285 | 2.462 | 2.252 |
| ST16 | 7.473 | 3.063 | 2.283 | 1.791 | 2.354 | 2.537 | 2.321 |
| ST17 | 7.363 | 3.018 | 2.250 | 1.764 | 2.319 | 2.500 | 2.286 |
Health Risk Index (HRI) via ingestion pathway for Cu concentration.
| (6–12 months) | (6–11 years) | (11–16 years) | (16–18 years) | (18–21 years) | (≥21 years) | (>65 years) | |
|---|---|---|---|---|---|---|---|
| ST1 | 9.010E−02 | 6.716E−02 | 5.266E−02 | 6.923E−02 | 7.462E−02 | 2.198E−01 | 6.825E−02 |
| ST2 | 8.672E−02 | 6.464E−02 | 5.069E−02 | 6.663E−02 | 7.182E−02 | 2.115E−01 | 6.569E−02 |
| ST3 | 8.334E−02 | 6.212E−02 | 4.871E−02 | 6.404E−02 | 6.902E−02 | 2.033E−01 | 6.313E−02 |
| ST4 | 6.420E−02 | 4.785E−02 | 3.752E−02 | 4.933E−02 | 5.317E−02 | 1.566E−01 | 4.863E−02 |
| ST5 | 6.082E−02 | 4.533E−02 | 3.555E−02 | 4.673E−02 | 5.037E−02 | 1.484E−01 | 4.607E−02 |
| ST6 | 6.082E−02 | 4.533E−02 | 3.555E−02 | 4.673E−02 | 5.037E−02 | 1.484E−01 | 4.607E−02 |
| ST7 | 6.307E−02 | 4.701E−02 | 3.686E−02 | 4.846E−02 | 5.223E−02 | 1.538E−01 | 4.778E−02 |
| ST8 | 6.420E−02 | 4.785E−02 | 3.752E−02 | 4.933E−02 | 5.317E−02 | 1.566E−01 | 4.863E−02 |
| ST9 | 6.532E−02 | 4.869E−02 | 3.818E−02 | 5.019E−02 | 5.410E−02 | 1.593E−01 | 4.948E−02 |
| ST10 | 6.645E−02 | 4.953E−02 | 3.884E−02 | 5.106E−02 | 5.503E−02 | 1.621E−01 | 5.033E−02 |
| ST11 | 6.758E−02 | 5.037E−02 | 3.950E−02 | 5.192E−02 | 5.596E−02 | 1.648E−01 | 5.119E−02 |
| ST12 | 7.096E−02 | 5.289E−02 | 4.147E−02 | 5.452E−02 | 5.876E−02 | 1.731E−01 | 5.375E−02 |
| ST13 | 7.321E−02 | 5.457E−02 | 4.279E−02 | 5.625E−02 | 6.063E−02 | 1.786E−01 | 5.545E−02 |
| ST14 | 7.321E−02 | 5.457E−02 | 4.279E−02 | 5.625E−02 | 6.063E−02 | 1.786E−01 | 5.545E−02 |
| ST15 | 7.433E−02 | 5.541E−02 | 4.345E−02 | 5.712E−02 | 6.156E−02 | 1.813E−01 | 5.631E−02 |
| ST16 | 7.659E−02 | 5.708E−02 | 4.476E−02 | 5.885E−02 | 6.343E−02 | 1.868E−01 | 5.801E−02 |
| ST17 | 7.546E−02 | 5.625E−02 | 4.411E−02 | 5.798E−02 | 6.249E−02 | 1.841E−01 | 5.716E−02 |
Average daily dose (ADD) via ingestion pathway for Zn concentration.
| (6–12 months) | (6–11 years) | (11–16 years) | (16–18 years) | (18–21 years) | (≥21 years) | (>65 years) | |
|---|---|---|---|---|---|---|---|
| ST1 | 21.841 | 8.954 | 6.674 | 5.233 | 6.880 | 7.415 | 6.782 |
| ST2 | 11.991 | 4.916 | 3.664 | 2.873 | 3.777 | 4.071 | 3.724 |
| ST3 | 10.773 | 4.416 | 3.292 | 2.581 | 3.393 | 3.657 | 3.345 |
| ST4 | 25.581 | 10.487 | 7.817 | 6.130 | 8.058 | 8.685 | 7.944 |
| ST5 | 23.085 | 9.464 | 7.054 | 5.531 | 7.272 | 7.838 | 7.169 |
| ST6 | 26.833 | 11.001 | 8.199 | 6.430 | 8.452 | 9.110 | 8.333 |
| ST7 | 15.664 | 6.422 | 4.786 | 3.753 | 4.934 | 5.318 | 4.864 |
| ST8 | 24.331 | 9.975 | 7.435 | 5.830 | 7.664 | 8.261 | 7.556 |
| ST9 | 14.437 | 5.919 | 4.412 | 3.459 | 4.548 | 4.902 | 4.483 |
| ST10 | 36.703 | 15.047 | 11.215 | 8.795 | 11.561 | 12.461 | 11.398 |
| ST11 | 86.428 | 35.433 | 26.410 | 20.710 | 27.225 | 29.344 | 26.839 |
| ST12 | 31.693 | 12.993 | 9.684 | 7.594 | 9.983 | 10.760 | 9.842 |
| ST13 | 48.132 | 19.732 | 14.708 | 11.533 | 15.162 | 16.342 | 14.947 |
| ST14 | 55.871 | 22.905 | 17.073 | 13.388 | 17.599 | 18.969 | 17.350 |
| ST15 | 43.026 | 17.639 | 13.147 | 10.310 | 13.553 | 14.608 | 13.361 |
| ST16 | 58.472 | 23.972 | 17.867 | 14.011 | 18.419 | 19.852 | 18.158 |
| ST17 | 32.941 | 13.505 | 10.066 | 7.893 | 10.377 | 11.184 | 10.230 |
Health Risk Index (HRI) via ingestion pathway for Zn concentration.
| (6–12 months) | (6–11 years) | (11–16 years) | (16–18 years) | (18–21 years) | (≥21 years) | (>65 years) | |
|---|---|---|---|---|---|---|---|
| ST1 | 2.985E−02 | 2.225E−02 | 1.744E−02 | 2.293E−02 | 2.472E−02 | 7.280E−02 | 2.261E−02 |
| ST2 | 1.639E−02 | 1.221E−02 | 9.578E−03 | 1.259E−02 | 1.357E−02 | 3.997E−02 | 1.241E−02 |
| ST3 | 1.472E−02 | 1.097E−02 | 8.604E−03 | 1.131E−02 | 1.219E−02 | 3.591E−02 | 1.115E−02 |
| ST4 | 3.496E−02 | 2.606E−02 | 2.043E−02 | 2.686E−02 | 2.895E−02 | 8.527E−02 | 2.648E−02 |
| ST5 | 3.155E−02 | 2.351E−02 | 1.844E−02 | 2.424E−02 | 2.613E−02 | 7.695E−02 | 2.390E−02 |
| ST6 | 3.667E−02 | 2.733E−02 | 2.143E−02 | 2.817E−02 | 3.037E−02 | 8.944E−02 | 2.778E−02 |
| ST7 | 2.141E−02 | 1.595E−02 | 1.251E−02 | 1.645E−02 | 1.773E−02 | 5.221E−02 | 1.621E−02 |
| ST8 | 3.325E−02 | 2.478E−02 | 1.943E−02 | 2.555E−02 | 2.754E−02 | 8.110E−02 | 2.519E−02 |
| ST9 | 1.973E−02 | 1.471E−02 | 1.153E−02 | 1.516E−02 | 1.634E−02 | 4.812E−02 | 1.494E−02 |
| ST10 | 5.016E−02 | 3.738E−02 | 2.932E−02 | 3.854E−02 | 4.154E−02 | 1.223E−01 | 3.799E−02 |
| ST11 | 1.181E−01 | 8.803E−02 | 6.903E−02 | 9.075E−02 | 9.781E−02 | 2.881E−01 | 8.946E−02 |
| ST12 | 4.331E−02 | 3.228E−02 | 2.531E−02 | 3.328E−02 | 3.587E−02 | 1.056E−01 | 3.281E−02 |
| ST13 | 6.577E−02 | 4.903E−02 | 3.844E−02 | 5.054E−02 | 5.447E−02 | 1.604E−01 | 4.982E−02 |
| ST14 | 7.635E−02 | 5.691E−02 | 4.463E−02 | 5.866E−02 | 6.323E−02 | 1.862E−01 | 5.783E−02 |
| ST15 | 5.880E−02 | 4.382E−02 | 3.437E−02 | 4.518E−02 | 4.869E−02 | 1.434E−01 | 4.454E−02 |
| ST16 | 7.991E−02 | 5.956E−02 | 4.670E−02 | 6.140E−02 | 6.617E−02 | 1.949E−01 | 6.053E−02 |
| ST17 | 4.502E−02 | 3.355E−02 | 2.631E−02 | 3.459E−02 | 3.728E−02 | 1.098E−01 | 3.410E−02 |
Average daily dose (ADD) via ingestion pathway for Ni concentration.
| (6–12 months) | (6–11 years) | (11–16 years) | (16–18 years) | (18–21 years) | (≥21 years) | (>65 years) | |
|---|---|---|---|---|---|---|---|
| ST1 | 2.747 | 1.126 | 0.839 | 0.658 | 0.865 | 0.933 | 0.853 |
| ST2 | 3.187 | 1.306 | 0.974 | 0.764 | 1.004 | 1.082 | 0.990 |
| ST3 | 3.516 | 1.442 | 1.075 | 0.843 | 1.108 | 1.194 | 1.092 |
| ST4 | 0.549 | 0.225 | 0.168 | 0.132 | 0.173 | 0.187 | 0.171 |
| ST5 | 0.659 | 0.270 | 0.201 | 0.158 | 0.208 | 0.224 | 0.205 |
| ST6 | 0.769 | 0.315 | 0.235 | 0.184 | 0.242 | 0.261 | 0.239 |
| ST7 | 1.099 | 0.451 | 0.336 | 0.263 | 0.346 | 0.373 | 0.341 |
| ST8 | 1.319 | 0.541 | 0.403 | 0.316 | 0.415 | 0.448 | 0.410 |
| ST9 | 1.538 | 0.631 | 0.470 | 0.369 | 0.485 | 0.522 | 0.478 |
| ST10 | 1.758 | 0.721 | 0.537 | 0.421 | 0.554 | 0.597 | 0.546 |
| ST11 | 1.978 | 0.811 | 0.604 | 0.474 | 0.623 | 0.672 | 0.614 |
| ST12 | 2.198 | 0.901 | 0.672 | 0.527 | 0.692 | 0.746 | 0.683 |
| ST13 | 2.527 | 1.036 | 0.772 | 0.606 | 0.796 | 0.858 | 0.785 |
| ST14 | 2.637 | 1.081 | 0.806 | 0.632 | 0.831 | 0.895 | 0.819 |
| ST15 | 3.077 | 1.261 | 0.940 | 0.737 | 0.969 | 1.045 | 0.956 |
| ST16 | 3.297 | 1.352 | 1.007 | 0.790 | 1.038 | 1.119 | 1.024 |
| ST17 | 3.516 | 1.442 | 1.075 | 0.843 | 1.108 | 1.194 | 1.092 |
Health Risk Index (HRI) via ingestion pathway for Ni concentration.
| (6–12 months) | (6–11 years) | (11–16 years) | (16–18 years) | (18–21 years) | (≥21 years) | (>65 years) | |
|---|---|---|---|---|---|---|---|
| ST1 | 5.631E−02 | 4.197E−02 | 3.291E−02 | 4.327E−02 | 4.664E−02 | 1.374E−01 | 4.266E−02 |
| ST2 | 6.532E−02 | 4.869E−02 | 3.818E−02 | 5.019E−02 | 5.410E−02 | 1.593E−01 | 4.948E−02 |
| ST3 | 7.208E−02 | 5.373E−02 | 4.213E−02 | 5.538E−02 | 5.970E−02 | 1.758E−01 | 5.460E−02 |
| ST4 | 1.126E−02 | 8.395E−03 | 6.583E−03 | 8.654E−03 | 9.327E−03 | 2.747E−02 | 8.531E−03 |
| ST5 | 1.352E−02 | 1.007E−02 | 7.899E−03 | 1.038E−02 | 1.119E−02 | 3.297E−02 | 1.024E−02 |
| ST6 | 1.577E−02 | 1.175E−02 | 9.216E−03 | 1.212E−02 | 1.306E−02 | 3.846E−02 | 1.194E−02 |
| ST7 | 2.253E−02 | 1.679E−02 | 1.317E−02 | 1.731E−02 | 1.865E−02 | 5.495E−02 | 1.706E−02 |
| ST8 | 2.703E−02 | 2.015E−02 | 1.580E−02 | 2.077E−02 | 2.239E−02 | 6.593E−02 | 2.048E−02 |
| ST9 | 3.154E−02 | 2.351E−02 | 1.843E−02 | 2.423E−02 | 2.612E−02 | 7.692E−02 | 2.389E−02 |
| ST10 | 3.604E−02 | 2.686E−02 | 2.107E−02 | 2.769E−02 | 2.985E−02 | 8.791E−02 | 2.730E−02 |
| ST11 | 4.055E−02 | 3.022E−02 | 2.370E−02 | 3.115E−02 | 3.358E−02 | 9.890E−02 | 3.071E−02 |
| ST12 | 4.505E−02 | 3.358E−02 | 2.633E−02 | 3.462E−02 | 3.731E−02 | 1.099E−01 | 3.413E−02 |
| ST13 | 5.181E−02 | 3.862E−02 | 3.028E−02 | 3.981E−02 | 4.291E−02 | 1.264E−01 | 3.924E−02 |
| ST14 | 5.406E−02 | 4.030E−02 | 3.160E−02 | 4.154E−02 | 4.477E−02 | 1.319E−01 | 4.095E−02 |
| ST15 | 6.307E−02 | 4.701E−02 | 3.686E−02 | 4.846E−02 | 5.223E−02 | 1.538E−01 | 4.778E−02 |
| ST16 | 6.758E−02 | 5.037E−02 | 3.950E−02 | 5.192E−02 | 5.596E−02 | 1.648E−01 | 5.119E−02 |
| ST17 | 7.208E−02 | 5.373E−02 | 4.213E−02 | 5.538E−02 | 5.970E−02 | 1.758E−01 | 5.460E−02 |
Average daily dose (ADD) via ingestion pathway for As concentration.
| (6–12 months) | (6–11 years) | (11–16 years) | (16–18 years) | (18–21 years) | (≥21 years) | (>65 years) | |
|---|---|---|---|---|---|---|---|
| ST1 | 4.066 | 1.667 | 1.242 | 0.974 | 1.281 | 1.380 | 1.263 |
| ST2 | 4.066 | 1.667 | 1.242 | 0.974 | 1.281 | 1.380 | 1.263 |
| ST3 | 5.824 | 2.388 | 1.780 | 1.396 | 1.835 | 1.977 | 1.809 |
| ST4 | 5.824 | 2.388 | 1.780 | 1.396 | 1.835 | 1.977 | 1.809 |
| ST5 | 5.385 | 2.208 | 1.645 | 1.290 | 1.696 | 1.828 | 1.672 |
| ST6 | 5.165 | 2.117 | 1.578 | 1.238 | 1.627 | 1.754 | 1.604 |
| ST7 | 4.396 | 1.802 | 1.343 | 1.053 | 1.385 | 1.492 | 1.365 |
| ST8 | 3.626 | 1.487 | 1.108 | 0.869 | 1.142 | 1.231 | 1.126 |
| ST9 | 3.516 | 1.442 | 1.075 | 0.843 | 1.108 | 1.194 | 1.092 |
| ST10 | 3.407 | 1.397 | 1.041 | 0.816 | 1.073 | 1.157 | 1.058 |
| ST11 | 3.736 | 1.532 | 1.142 | 0.895 | 1.177 | 1.269 | 1.160 |
| ST12 | 4.945 | 2.027 | 1.511 | 1.185 | 1.558 | 1.679 | 1.536 |
| ST13 | 3.407 | 1.397 | 1.041 | 0.816 | 1.073 | 1.157 | 1.058 |
| ST14 | 4.615 | 1.892 | 1.410 | 1.106 | 1.454 | 1.567 | 1.433 |
| ST15 | 6.264 | 2.568 | 1.914 | 1.501 | 1.973 | 2.127 | 1.945 |
| ST16 | 6.703 | 2.748 | 2.048 | 1.606 | 2.112 | 2.276 | 2.082 |
| ST17 | 8.352 | 3.424 | 2.552 | 2.001 | 2.631 | 2.836 | 2.594 |
Health Risk Index (HRI) via ingestion pathway for As concentration.
| (6–12 months) | (6–11 years) | (11–16 years) | (16–18 years) | (18–21 years) | (≥21 years) | (>65 years) | |
|---|---|---|---|---|---|---|---|
| ST1 | 5.556E+00 | 4.141E+00 | 3.248E+00 | 4.269E+00 | 4.602E+00 | 1.355E+01 | 4.209E+00 |
| ST2 | 5.556E+00 | 4.141E+00 | 3.248E+00 | 4.269E+00 | 4.602E+00 | 1.355E+01 | 4.209E+00 |
| ST3 | 7.959E+00 | 5.932E+00 | 4.652E+00 | 6.115E+00 | 6.591E+00 | 1.941E+01 | 6.029E+00 |
| ST4 | 7.959E+00 | 5.932E+00 | 4.652E+00 | 6.115E+00 | 6.591E+00 | 1.941E+01 | 6.029E+00 |
| ST5 | 7.358E+00 | 5.485E+00 | 4.301E+00 | 5.654E+00 | 6.094E+00 | 1.795E+01 | 5.574E+00 |
| ST6 | 7.058E+00 | 5.261E+00 | 4.125E+00 | 5.423E+00 | 5.845E+00 | 1.722E+01 | 5.346E+00 |
| ST7 | 6.007E+00 | 4.477E+00 | 3.511E+00 | 4.615E+00 | 4.975E+00 | 1.465E+01 | 4.550E+00 |
| ST8 | 4.956E+00 | 3.694E+00 | 2.896E+00 | 3.808E+00 | 4.104E+00 | 1.209E+01 | 3.754E+00 |
| ST9 | 4.805E+00 | 3.582E+00 | 2.809E+00 | 3.692E+00 | 3.980E+00 | 1.172E+01 | 3.640E+00 |
| ST10 | 4.655E+00 | 3.470E+00 | 2.721E+00 | 3.577E+00 | 3.855E+00 | 1.136E+01 | 3.526E+00 |
| ST11 | 5.106E+00 | 3.806E+00 | 2.984E+00 | 3.923E+00 | 4.228E+00 | 1.245E+01 | 3.868E+00 |
| ST12 | 6.758E+00 | 5.037E+00 | 3.950E+00 | 5.192E+00 | 5.596E+00 | 1.648E+01 | 5.119E+00 |
| ST13 | 4.655E+00 | 3.470E+00 | 2.721E+00 | 3.577E+00 | 3.855E+00 | 1.136E+01 | 3.526E+00 |
| ST14 | 6.307E+00 | 4.701E+00 | 3.686E+00 | 4.846E+00 | 5.223E+00 | 1.538E+01 | 4.778E+00 |
| ST15 | 8.560E+00 | 6.380E+00 | 5.003E+00 | 6.577E+00 | 7.089E+00 | 2.088E+01 | 6.484E+00 |
| ST16 | 9.160E+00 | 6.828E+00 | 5.354E+00 | 7.038E+00 | 7.586E+00 | 2.234E+01 | 6.939E+00 |
| ST17 | 1.141E+01 | 8.507E+00 | 6.671E+00 | 8.769E+00 | 9.452E+00 | 2.784E+01 | 8.645E+00 |
Average daily dose (ADD) via ingestion pathway for Pb concentration.
| (6–12 months) | (6–11 years) | (11–16 years) | (16–18 years) | (18–21 years) | (≥21 years) | (>65 years) | |
|---|---|---|---|---|---|---|---|
| ST1 | ND | ND | ND | ND | ND | ND | ND |
| ST2 | ND | ND | ND | ND | ND | ND | ND |
| ST3 | ND | ND | ND | ND | ND | ND | ND |
| ST4 | 1.099 | 0.451 | 0.336 | 0.263 | 0.346 | 0.373 | 0.341 |
| ST5 | 0.769 | 0.315 | 0.235 | 0.184 | 0.242 | 0.261 | 0.239 |
| ST6 | 0.769 | 0.315 | 0.235 | 0.184 | 0.242 | 0.261 | 0.239 |
| ST7 | ND | ND | ND | ND | ND | ND | ND |
| ST8 | ND | ND | ND | ND | ND | ND | ND |
| ST9 | ND | ND | ND | ND | ND | ND | ND |
| ST10 | ND | ND | ND | ND | ND | ND | ND |
| ST11 | ND | ND | ND | ND | ND | ND | ND |
| ST12 | ND | ND | ND | ND | ND | ND | ND |
| ST13 | ND | ND | ND | ND | ND | ND | ND |
| ST14 | ND | ND | ND | ND | ND | ND | ND |
| ST15 | ND | ND | ND | ND | ND | ND | ND |
| ST16 | ND | ND | ND | ND | ND | ND | ND |
| ST17 | ND | ND | ND | ND | ND | ND | ND |
Health Risk Index (HRI) via ingestion pathway for Pb concentration.
| (6–12 months) | (6–11 years) | (11–16 years) | (16–18 years) | (18–21 years) | (≥21 years) | (>65 years) | |
|---|---|---|---|---|---|---|---|
| ST1 | ND | ND | ND | ND | ND | ND | ND |
| ST2 | ND | ND | ND | ND | ND | ND | ND |
| ST3 | ND | ND | ND | ND | ND | ND | ND |
| ST4 | 3.218E−01 | 2.399E−01 | 1.881E−01 | 2.473E−01 | 2.665E−01 | 7.849E−01 | 2.438E−01 |
| ST5 | 2.253E−01 | 1.679E−01 | 1.317E−01 | 1.731E−01 | 1.865E−01 | 5.495E−01 | 1.706E−01 |
| ST6 | 2.253E−01 | 1.679E−01 | 1.317E−01 | 1.731E−01 | 1.865E−01 | 5.495E−01 | 1.706E−01 |
| ST7 | ND | ND | ND | ND | ND | ND | ND |
| ST8 | ND | ND | ND | ND | ND | ND | ND |
| ST9 | ND | ND | ND | ND | ND | ND | ND |
| ST10 | ND | ND | ND | ND | ND | ND | ND |
| ST11 | ND | ND | ND | ND | ND | ND | ND |
| ST12 | ND | ND | ND | ND | ND | ND | ND |
| ST13 | ND | ND | ND | ND | ND | ND | ND |
| ST14 | ND | ND | ND | ND | ND | ND | ND |
| ST15 | ND | ND | ND | ND | ND | ND | ND |
| ST16 | ND | ND | ND | ND | ND | ND | ND |
| ST17 | ND | ND | ND | ND | ND | ND | ND |
| Subject area | Water Resources and Environmental Engineering |
| More specific subject area | Surface Water Quality and health-risk assessment |
| Type of data | Tables and figure |
| How data was acquired | River visits, Samples were collected during the wet season into a high density polyethene containers, ionic concentration analysis using standard methods |
| Data format | Filtered, analyzed |
| Experimental factors | Measuring the values of heavy metal ion content of surface water samples. Calculating the human health risk assessment after the concentration of heavy metals were obtained. |
| Experimental features | Determining the possible concentration levels of some selected Heavy Metals in River water samples at specific points were inhabitants collect water for various uses. Samples collected were preserved as stipulated by standard. After which, proper analysis was carried out. |
| Data source location | Adodo-Ota, Ogun State, Nigeria. Latitude 6°40′58.52′′N-6°41′23.92′′N and Longitude 3°8′53.87′′E - 3°8′57.86′′E. |
| Related research article | The data are available with this article |